Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Author:

Noy Ariela12,de Vos Sven3,Thieblemont Catherine4,Martin Peter2,Flowers Christopher R.5,Morschhauser Franck6,Collins Graham P.7,Ma Shuo8,Coleman Morton9,Peles Shachar10,Smith Stephen1112,Barrientos Jacqueline C.13,Smith Alina14,Munneke Brian14,Dimery Isaiah14,Beaupre Darrin M.14,Chen Robert15

Affiliation:

1. Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

2. Weill Department of Medicine, Weill Cornell Medical College, New York, NY;

3. David Geffen School of Medicine at UCLA, Los Angeles, CA;

4. Hemato-oncology Department, Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris Diderot University, Sorbonne Paris-Cité, Paris, France;

5. Winship Cancer Institute of Emory University, Atlanta, GA;

6. Hematologie, Centre Hospitalier Universitaire, Université de Lille, Lille, France;

7. Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;

8. Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL;

9. Clinical Research Alliance, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY;

10. Florida Cancer Specialists, Atlantis, FL;

11. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA;

12. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

13. Division of Hematology and Medical Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, NY;

14. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and

15. City of Hope National Medical Center, Duarte, CA

Abstract

Key Points Single-agent ibrutinib induced durable remissions (ORR 48%) with a favorable benefit–risk profile in patients with previously treated MZL. Inhibition of BCR signaling with ibrutinib provides a treatment option without chemotherapy for an MZL population with high unmet need.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3